Single Center Experience With Long-term Ustekinumab in Patients With Refractory Crohnʼs Disease (Prior Anti-TNF and Vedolizumab Therapy)

Authors :: Dawn B. Beaulieu
Sara N. Horst
Lauren Evers
Kim Annis
Caroline Duley
Audrey L. Bennett
Dawn W. Adams
David A. Schwartz
Source :: American Journal of Gastroenterology. 112:S397-S399
Publication Year :: 2017
Publisher :: Ovid Technologies (Wolters Kluwer Health), 2017.

Subjects :: medicine.medical_specialty
Hepatology
business.industry
Gastroenterology
Disease
Single Center
Vedolizumab
Refractory
Internal medicine
Ustekinumab
medicine
Tumor necrosis factor alpha
In patient
business
medicine.drug

Full Text Access

Tools